Zinc lozenges may shorten the duration of colds: A systematic review

Open Respiratory Medicine Journal

Volumn 5, Issue 1, 2011, Pages 51-58

  Hemilä, Harri ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Meta analysis; Randomized controlled trials; Respiratory infections; Zinc

Indexed keywords

ACETIC ACID DERIVATIVE; PLACEBO; ZINC; ZINC DERIVATIVE;

ARTICLE; COMMON COLD; CONSTIPATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GENETIC HETEROGENEITY; HUMAN; LOW DRUG DOSE; LOZENGE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TASTE DISORDER; TREATMENT RESPONSE;

EID: 80053550885     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401105010051     Document Type: Article

References (55)

1. Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med 2008; 14: 353-7.
2. Walker FC, Black RE. Zinc and the risk for infectious disease. Annu Rev Nutr 2004; 24: 255-75.
3. Aggarwal R, Sentz J, Miller MA. Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a metaanalysis. Pediatrics 2007; 119: 1120-30.
4. Kurugöl Z, Akilli M, Bayram N, Koturoglu G. The prophylactic and therapeutic effectiveness of zinc sulphate on common cold in children. Acta Paediatr 2006; 95: 1175-81.
5. Girodon F, Galan P, Monget AL, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients. Arch Intern Med 1999; 159: 748-54.
6. Avenell A, Campbell MK, Cook JA, et al. Effect of multivitamin and multimineral supplements on morbidity from infections in older people (MAVIS trial): pragmatic, randomised, double blind, placebo controlled trial. BMJ 2005; 331: 324-9.
7. Eby GA, Davis DR, Halcomb WW. Reduction in duration of common cold by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother 1984; 25: 20-4.
8. Godfrey JC. Zinc for the common cold. Antimicrob Agents Chemother 1988; 32: 605-6.
9. Eby GA. Stability constants of zinc complexes affect common cold treatment results. Antimicrob Agents Chemother 1988; 32: 606-7. http://aac.asm.org/cgi/reprint/32/4/606
10. Martin RB. pH as a variable in free zinc ion concentration from zinc-containing lozenges. Antimicrob Agents Chemother 1988; 32: 608-9.
11. Eby GA. Zinc ion availability - the determinant of efficacy in zinc lozenge treatment of common colds. J Antimicrob Chemother 1997; 40: 483-93.
12. Bakar NKA, Taylor DM, Williams DR. The chemical speciation of zinc in human saliva: possible correlation with reduction of the symptoms of the common cold produced by zinc gluconatecontaining lozenges. Chem Spec Bioavailab 1999; 11: 95-101.
13. Eby GA. Zinc lozenges: cold cure or candy? Solution chemistry determinations. Biosci Rep 2004; 24: 23-39.
14. Eby GA. Zinc lozenges as cure for the common cold - a review and hypothesis. Med Hypotheses 2010; 74: 482-92.
15. Zarembo JE, Godfrey JC, Godfrey NJ. Zinc(II) in saliva: determination of concentrations produced by different formulations of zinc gluconate lozenges containing common excipients. J Pharm Sci 1992; 81: 128-30.
16. Goodwin JS, Tangum MR. Battling quackery: attitudes about micronutrient supplements in American Academic medicine. Arch Intern Med 1998; 158: 2187-91.
17. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-13.
18. [Higgins JPT, Green S, Eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Sections 5.4.1 and 8.3.3. Available: www.cochrane-handbook.org [Accessed 2011 May 2].
19. Smith DS, Helzner EC, Nuttall CE Jr, et al. Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother 1989; 33: 646-8.
20. Godfrey JC, Conant-Sloane B, Turco JH, Mercer N, Godfrey NJ. Zinc gluconate and the common cold: a controlled clinical study. J Int Med Res 1992; 20: 234-46.
21. Prasad AS, Beck FW, Bao B, Snell D, Fitzgerald JT. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. J Infect Dis 2008; 197: 795-802.
22. Petrus EJ, Lawson KA, Bucci LR, Blum K. Randomized, doublemasked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects. Curr Ther Res 1998; 59: 595-607.
23. Turner RB, Cetnarowski WE. Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds. Clin Infect Dis 2000; 31: 1202-8.
24. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1996; 125: 81-8.
25. Prasad AS, Fitzgerald JT, Bao B, Beck FW, Chandrasekar PH. Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 2000; 133: 245-52.
26. Douglas RM, Miles HB, Moore BW, Ryan P, Pinnock CB. Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory infection in Australian adults. Antimicrob Agents Chemother 1987; 31: 1263-5.
27. Macknin ML, Piedmonte M, Calendine C, Janosky J, Wald E. Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial. JAMA 1998; 279: 1962-7.
28. Weismann K, Jakobsen JP, Weismann JE, et al. Zinc gluconate lozenges for common cold: a double-blind clinical trial. Dan Med Bull 1990; 37: 279-81.
29. Eby GA, Halcomb WW. Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold treatment: A double-blind, placebo-controlled clinical trial. Altern Ther Health Med 2006; 12: 34-8.
30. Hemilä H, Herman ZS. Vitamin C and the common cold: a retrospective analysis of Chalmers' review. J Am Coll Nutr 1995; 14: 116-23.
31. [Hemilä H. Do vitamins C and E affect respiratory infections? Helsinki, Finland: University of Helsinki 2006; 36-8. Available at: https://oa.doria.fi/handle/10024/1540 [Accessed: May 2, 2011].
32. Hemilä H, Chalker EB, Douglas RM. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2007: CD000980. doi:10.1002/14651858.CD000980.pub3
33. [RA. Combining independent tests of significance. Am Stat 1948; 2: 30. Available at: http://digital.library.adelaide.edu.au/coll/special//fisher/224A.pdf [Accessed: May 2, 2011].
34. Loughin TM. A systematic comparison of methods for combining p-values from independent tests. Comput Stat Data Anal 2004; 47: 467-85.
35. Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. http://ims.cochrane.org/revman
36. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003; 327: 557-60.
37. Al-Nakib W, Higgins PG, Barrow I, Batstone G, Tyrrell DA. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother 1987; 20: 893-901.
38. Smith AP, Tyrrell DAJ, Al-Nakib W, Barrow I, Higgins P, Wenham R. Effects of zinc gluconate and nedocromil sodium on performance deficits produced by the common cold. J Psychopharmacol 1991; 5(3): 251-4.
39. Farr BM, Conner EM, Betts RF, et al. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother 1987; 31: 1183-7.
40. Eby GA. Elimination of efficacy by additives in zinc acetate lozenges for common colds. Clin Infect Dis 2001; 32: 1520.
41. Pories WJ, Henzel JH, Rob CG, Strain WH. Acceleration of wound healing in man with zinc sulphate given by mouth. Lancet 1967; 1: 121-4.
42. Hallböök T, Laner E. Serum-zinc and healing of venous leg ulcers. Lancet 1972; 2: 780-2.
43. Simkin PA. Oral zinc sulphate in rheumatoid arthritis. Lancet 1976; 2: 539-42.
44. Prasad AS, Brewer GJ, Schoomaker EB, Rabbani P. Hypocupremia induced by zinc therapy in adults. JAMA 1978; 240: 2166-8.
45. Hoffman HN, Phyliky RL, Fleming CR. Zinc-induced copper deficiency. Gastroenterology 1988; 94: 508-12.
46. Samman S, Roberts DC. The effect of zinc supplements on plasma zinc and copper levels and the reported symptoms in healthy volunteers. Med J Aust 1987; 146: 246-9.
47. Jackson JL, Peterson C, Lesho E. A meta-analysis of zinc salts lozenges and the common cold. Arch Intern Med 1997; 157: 2373-6.
48. Jackson JL, Lesho E, Peterson C. Zinc and the common cold: a meta-analysis revisited. J Nutr 2000; 130(5S Suppl): 1512S-5S.
49. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351-5.
50. Caruso TJ, Prober CG, Gwaltney JM. Treatment of naturally acquired common colds with zinc: a structured review. Clin Infect Dis 2007; 45: 569-74.
51. Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002; 287: 2973-82.
52. Eby GA. Therapeutic effectiveness of ionic zinc for common colds. Clin Infect Dis 2008; 46: 483-4.
53. Chalmers TC. Effects of ascorbic acid on the common cold: an evaluation of the evidence. Am J Med 1975; 58: 532-6.
54. Hemilä H. Vitamin C, the placebo effect, and the common cold: a case study of how preconceptions influence the analysis of results. J Clin Epidemiol 1996; 49: 1079-84.
55. Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev 2011:CD001364.